Related information appears in other stories and tables in this issue Also see "Contamination Issues Drove Drug Recalls to Record Levels in 2011" - Pink Sheet, 28 March, 2012. ([A#08120328002]) ([A#08120328003]) ([A#08120328009]). Open, download and search a first-ever database from “The Gold Sheet” of last year’s drug recall information.
Drug Product Recalls In 2011: Categorized By Problem Area
This table lists every drug recall of 2011, along with a description of the drug product, the manufacturer, the recaller, the recall class and the reason for the recall.
More from Manufacturing
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
More from Compliance
• By
Results from a single-arm study cannot support representations on overall survival, progression-free survival and disease control rate for the cancer drug, the Office of Prescription Drug Promotion said in another “untitled” letter implicating the agency’s CFL guidance.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.